Abstract
Discovery and development of carbonic anhydrase inhibitors is crucial for their clinical use as antiepileptic, diurectic and antiglaucoma agents. Keeping this in mind, we have synthesized carbohydrazones 1-27 and evaluated them for their in vitro carbonic anhydrase inhibitory potential. Out of twenty-seven compounds, compounds 1 (IC
=1.33±0.01µM), 2 (IC
=1.85±0.24µM), 3 (IC
=1.37±0.06µM), and 9 (IC
=1.46±0.12µM) have showed carbonic anhydrase inhibition better than the standard drug zonisamide (IC
=1.86±0.03µM). Moreover, compounds 4 (IC
=2.32±0.04µM), 5 (IC
=3.96±0.35µM), 7 (IC
=2.33±0.02µM), and 8 (IC
=2.67±0.01µM) showed good inhibitory activity. Cheminformatic analysis has shown that compounds 1 and 2 possess lead-like properties. In addition, kinetic and molecular docking studies were also performed to investigate the binding interaction between carbohydrazones and carbonic anhydrase enzyme. This study has identified a novel and potent class of carbonic anhydrase inhibitors with the potential to be investigated further.